IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

Impact of Digital Health Technologies on Patient Adherence to Medication Regimens

Kanchan Ganpat Sandbhor, Ms. Kalyani Bhor, Litej Anand Shirtar
Student, Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra.
Professor, Department of Quality Assurance Technique
Samarth Institute of Pharmacy, Belhe, Pune, Maharashtra
kanchansandbhor65@gmail.com, litejshirtar15@gmail.com

Abstract: *Medication non-adherence remains one of the most persistent barriers to the realization of optimal therapeutic outcomes in both chronic and infectious diseases. In the last few years, the rapid emergence of digital health technologies (DHTs) such as mobile health applications, wearable sensors, smart packing, electronic pill dispensers, and telehealth services, has transformed the approaches to facilitate and monitor medication adherence. This review takes a critical look at these changes shaped by the advent of digital health technologies in the initiation, implementation, and maintenance phases of adherence. There is evidence from a range of clinical contexts that DHTs can improve in medication-taking behaviour; this can be facilitated through the use of real-time reminders, personalized feedback, behavioural reinforcement, and data informed decision support.*

However, the results vary due to the study design, duration of follow up, patient engagement, and the access to technology across studies. In addition, issues related to digital literacy, data privacy, infrastructure, and sustainability can impact widespread adoption of DHTs. Nevertheless, DHTs have an opportunity to address bridging the adherence gap with careful design and integration within healthcare systems, as well as behaviour and education support. Future directions for research should focus on creating long-term, contextual, and cost-effective models that attend to the implementation of new technology, while balancing equitable access to care and patient-centred care.

Keywords: Digital health, medication adherence, mobile health, telemedicine, patient engagement, chronic disease management, healthcare technology

I. INTRODUCTION

Medication adherence—the extent to which patients take their medications as prescribed—remains a cornerstone of effective disease management and public health. Despite advances pharmacotherapy, non-adherence continues to compromise clinical outcomes, accounting for nearly half of all treatment failures in chronic conditions such as hypertension, diabetes, asthma, and cardiovascular disorders. The World Health Organization identifies medication non-adherence as a "hidden epidemic," contributing to increased hospitalizations, disease progression, and healthcare expenditures globally. The causes are multifactorial, ranging from forgetfulness and complex dosing schedules to psychological, socioeconomic, and communication barriers between patients and healthcare providers.

The emergence of digital health technologies (DHTs) has introduced innovative avenues to address these long-standing challenges. DHTs encompass a wide spectrum of tools, including mobile health (mHealth) applications, telemedicine platforms, wearable biosensors, smart pill dispensers, and artificial intelligence–based monitoring systems. These technologies aim not only to remind patients to take their medications but also to engage them through feedback mechanisms, real-time monitoring, behavioral reinforcement, and virtual health coaching. By integrating technology with behavioral science and personalized medicine, DHTs have the potential to transform medication adherence from a passive routine into an interactive, data-driven process.

DOI: 10.48175/IJARSCT-34805

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

Recent evidence suggests that DHTs can positively influence adherence across multiple therapeutic areas by improving patient engagement, promoting self-management, and enabling healthcare professionals to make timely, data-informed interventions. However, the magnitude and consistency of these effects remain variable, with several studies reporting short-term benefits that diminish over time. Barriers such as limited digital literacy, privacy concerns, technological cost, and unequal access further restrict their widespread adoption, particularly in low- and middle-income countries.

This review critically examines the impact of digital health technologies on patient adherence to medication regimens. It synthesizes current evidence across disease contexts, explores underlying behavioral mechanisms, and highlights practical and ethical considerations influencing implementation. Furthermore, it identifies research gaps and proposes future directions for leveraging digital innovations to achieve sustainable, equitable, and patient-centered medication adherence.

Fig: Benefit of Digital Transformation



Fig : Digital Pill

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2



Fig: Digital Health

Conceptual Framework

1.1 Phases of medication adherence

According to adherence literature, there are at least three phases:

1. Initiation – when the patient takes the first dose of a prescribed medication.
2. Implementation – how the patient's actual dosing corresponds to the prescribed regimen (dose, timing, frequency) over time.
3. Persistence – the length of time from initiation until discontinuation of therapy. PMC+1

A DHT may address one or more of these phases (for example reminder apps help with implementation; reminders + feedback may help persistence).

1.2 Mapping DHT functionalities to adherence mechanisms

- Reminders/alerts (apps, SMS, push notifications) → help with forgetfulness and timing of dose.
- Monitoring & tracking (smart pill dispensers, ingestible sensors, bio sensing, digital
- packaging) → provides objective data on whether medication was taken, reduces uncertainty, allows feedback.
- Education & behavioural support (apps, tele-counselling, gamification, incentives) → addresses knowledge gaps, motivation, self-efficacy.
- Communication/connectivity (app ↔ provider, telehealth) → strengthens patient-provider link, allows intervention when non-adherence detected.
- Analytics/personalisation (AI, machine learning) → predictive modelling of non-adherence risk, tailoring of interventions.

DOI: 10.48175/IJARSCT-34805

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

- In your review, you can propose a conceptual diagram connecting DHT features → mechanism of change (e.g., improved self-efficacy, reduced forgetfulness, improved habit formation, enhanced feedback) → adherence outcome → clinical/cost outcome.

1.3 Metrics/Outcomes

- Adherence metrics: percentage of doses taken, percentage of doses taken at correct time, medication possession ratio (MPR), persistence (time to discontinuation), missed doses.
- Clinical outcomes: disease control (e.g., HbA1c in diabetes, blood pressure in hypertension, sputum conversion in TB), hospitalization rates, complications, development of resistance.
- Patient-centred outcomes: engagement, satisfaction, quality of life, self-efficacy.
- Economic outcomes: cost-effectiveness of DHT interventions, healthcare utilisation.

III. EVIDENCE FROM DIFFERENT DISEASE CONTEXTS

It helps to structure this section by disease type (chronic non-communicable diseases vs infectious disease) to show breadth of evidence.

3.1 Chronic diseases (e.g., diabetes, hypertension, cardiovascular)

- In a review of digital health technologies in adult diabetes, the authors found mobile apps, SMS, telemonitoring showed improved medication adherence, better glycaemic control, but challenges remain (digital literacy, sustainability).
- In an integrative review for diabetes/hypertension, 13 studies were identified using DHTs (IVR, SMS, telemonitoring) but no conclusive evidence for long-term adherence improvement; many studies were short duration.
- This suggests: For NCDs, evidence is promising but mixed; factors such as study duration, size, heterogeneity, user engagement affect outcomes.

3.2 Infectious diseases (e.g., tuberculosis)

- In a systematic review of RCTs in TB patients, DHTs (video observed therapy, ingestible sensor, SMS reminders, medication monitoring boxes) were evaluated. Some RCTs showed significant improvements (OR/RR 1.10 to 7.69) in treatment completion, adherence, but others did not show significant effect.
- For example: of 16 RCTs, only some showed benefit; effect varied. This indicates that while DHTs have potential, effect is inconsistent and depends on context (infrastructure, patient population, technology acceptance).
- Additional qualitative work: e.g., in India, digital adherence technologies like 99DOTS, MERM showed promise but patient acceptance, access to phones, connectivity were barriers.

3.3 Other contexts / special technologies

- Biosensing/ingestible sensors: A review indicated digital medication systems (DMS) with ingestible sensors show substantial promise especially for high-risk meds (e.g., opioids, antipsychotics) where objective ingestion detection is important. But limited data, cost and latency issues remain.
- mHealth apps with gamification, social/community features: For instance, a retrospective real-world study of a mobile app (Perx Health) for chronic conditions found extremely high median implementation adherence (~96.6% at 3 months, ~96.8% at 6 months) in users of the app.
- This suggests that more advanced apps with multiple behavioural components (not just reminders) may achieve strong adherence—but real-world generalisability/selection bias must be considered.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

IV. KEY FINDINGS: BENEFITS & IMPACT

4.1 Benefits

- DHTs can improve medication adherence: some studies show significant improvements in adherence metrics (doses taken, timing, persistence) especially when features are multi- component (reminder + monitoring + education + feedback).
- They enable remote monitoring and reduce reliance on face-to-face interactions (important in rural/remote settings).
- They deliver timely feedback and data to both patient and provider, facilitating intervention when issues arise (e.g., missed doses).
- They can enhance patient engagement, self-management and empowerment (via apps, gamification, and interactive modules).
- They may improve clinical outcomes (glycaemic control, blood pressure, treatment completion in TB) and may reduce healthcare utilisation/costs (though more evidence needed).
- Example: In TB RCTs, some DHT interventions achieved odds ratios up to ~7.69 for treatment completion compared to control.

4.2 Impact on different adherence phases

- For implementation (correct dosing over time): reminders and monitoring tools show most effect.
- For persistence (continuing therapy): apps with behavioural components and feedback loops may help sustain therapy.
- For initiation: less evidence (many technologies assume medication has been initiated) — this is a gap.

4.3 Cost-effectiveness and healthcare system impact

- Some reviews suggest DHT may be cost-effective, especially in chronic care via reduced hospitalisations and improved disease control.
- They also support scaling of adherence support (mobile apps can reach many users at relatively low incremental cost) compared to high-intensity in-person interventions.

V. CHALLENGES, LIMITATIONS & BARRIERS

5.1 Technology & user-related barriers

- Digital literacy: older patients, patients in low-resource settings may struggle with apps, apps may not be user-friendly.
- Access & connectivity: in many regions mobile/internet access may be limited; signal issues, phone ownership may limit uptake.
- Sustained engagement: many interventions show improvements short-term (e.g., up to 3-6 months) but long-term adherence maintenance is less proven.
- Behaviour change complexity: adherence is influenced by many factors — beliefs, health literacy, side-effects, regimen complexity, cost, patient-provider relationship; technology alone may not suffice.

5.2 Evidence/Study Limitations

- Heterogeneity of studies: interventions differ vastly in design, disease population, adherence metrics, and duration— making comparisons and meta-analysis difficult.
- Short follow-up durations in many studies; fewer long-term data.
- Possible selection bias: users of adherence apps may be more motivated/tech-savvy, limiting generalisability.
- In many cases, the control group may receive usual care which varies widely.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

- Adherence measurement issues: many studies rely on self-report rather than objective monitoring. Self-report may over-estimate adherence.
- Cost and resource implications: sophisticated technologies (ingestible sensors, smart packaging) may be expensive and less scalable in low-resource settings.

5.3 Privacy, ethical and regulatory issues

- Data privacy/security: digital systems gather sensitive medication/health data; ensuring confidentiality and security is critical.
- Regulatory approvals: certain DHTs (especially ingestible sensors or medical-grade devices) may require regulatory clearance.
- Equity concerns: if digital solutions are deployed unequally, there is risk of increasing disparities (those without smartphones/ connectivity may be left behind).



Fig. Technology & user-related barriers



Fig. Evidence/Study Limitations

Implementation Considerations for Practice

When translating DHTs into real-world practice (especially relevant for India/LMICs context such as Maharashtra, India), consider:

- Patient and provider co-design: involve end-users in design of apps/tools to ensure usability and acceptability.
- Integration with healthcare workflows/EHRs: DHTs should ideally link with electronic health records, provider dashboards, care teams so that data can trigger actionable workflows.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

- Tailoring and personalization: technologies should adapt to individual patient's regimen complexity, preferences, language, and literacy.
- Training & support: patients (especially older or less tech-savvy) will need support/training in using digital tools.
- Behavioural components beyond reminders: simply reminding to take medication may be insufficient; include feedback, gamification, social components, and habit-formation strategies.
- Scalability and sustainability: choose technologies that are cost-effective, low-maintenance, suited to local infrastructure (connectivity, smartphone penetration).
- Monitoring & evaluation: use objective adherence measures where possible; plan for long- term follow-up to assess sustained adherence and outcomes.
- Addressing system issues: regimen complexity, side-effects, cost of meds, provider-patient communication must still be addressed in parallel—not only technology.
- Equity and access: ensure disadvantaged populations (rural, low-income, low-literacy) are not excluded; consider offline solutions or simpler technologies (SMS rather than smartphone apps).

Future Directions & Research Gaps

- Long-term effectiveness: More studies with long-term follow-up (12+ months or more) to assess sustained adherence and impact on clinical and cost outcomes.
- Comparative effectiveness: Which digital features/components are most effective (reminders only vs multi-component vs monitoring vs personalization)?
- Cost-effectiveness in LMIC contexts: Evidence on economics of DHTs in resource-limited settings is limited.
- Integration with AI/predictive analytics: Emerging research (e.g., adherence forecasting via LSTM/ CNN) suggests future personalized interventions.
- Tailored interventions for special populations: elderly, low-literacy, rural, low-income; adapt technology to their needs and constraints.
- Technology & regimen complexity: Studies exploring DHTs in complex regimens (polypharmacy, multiple comorbidities) are fewer.
- Implementation science focus: Understand barriers/facilitators to real-world uptake (beyond pilot RCTs), especially in diverse health-system contexts like India.
- Standardised adherence metrics & reporting: Need for consensus on how to measure and report adherence in digital interventions for comparability.
- Ethical, privacy, equity frameworks: More work needed on frameworks for safe, fair, accessible deployment of DHTs in medication adherence.
- Hybrid models: Combining digital + human support (nurse/pharmacist) may yield better outcomes; explore optimal mix.

Discussion

Digital health technologies (DHTs) offer a disruptive strategy to treatment non-adherence, which has plagued healthcare for decades. DHTs enable real-time data collection, personalized reminders, and timely feedback, providing patients opportunities to engage with their treatment and medication compliance. Engagement and motivation can be further enhanced through gamification, tracking progress, and virtual incentives. Additionally, the incorporation of artificial intelligence and predictive analytics allows health care providers to target patients for adherence intervention efforts based on personalized adherence risks.

Nevertheless, there are challenges to the full potential of DHTs. Digital disparities including limited smartphone access, low digital literacy, and lack of stable internet access act as barriers to uptake, especially in low-resource contexts. The sustainability of adherence to long-term interventions also remains unclear as many studies have demonstrated

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

diminished engagement over time. Concerns about privacy and trust, integration with technology, and patient receptivity have compounded issues with integration. Finally, the differences in study designs and outcome measures to assess adherence is difficult to determine a global standard.

Digital interventions may enhance—not replace—human-centric care. The best intervention strategies for medication adherence are those which integrate technology in order to compliment behavioral counseling from professionals as well as support from community resources. Future work should continue to promote the equitable, ethical, & sustainable integration of DHTs into health systems to empower patients over time.

VI. CONCLUSION

Digital health technology has developed into a strong tool for providing motivation for medication adherence, reducing the divide between patients and healthcare providers by creating connections, personalizing treatment approaches, and providing new data. While the effectiveness of these technologies varies, those well-designed and relevant to their context can enhance treatment outcomes and patient engagement significantly. The promise and potential of these technologies lies not in their novelty, but in integration - capturing digital health technology within the behavioral science domain, through policy initiatives, by delivering equity in accessible healthcare approaches. The future direction for researchers and practitioners is to engage in long-term evaluations, conduct cost-effectiveness analyses, and develop inclusive designs that ensure access for diverse populations. ALIGNING compassion and inclusivity with technological innovation provides the opportunity to enhance medication adherence and drive towards a global agenda of ongoing, engaging, patient- centered medication adherence for all.

VII. RESULTS

A review of current literature indicates that digital health technologies (DHTs) have shown measurable but inconsistent effectiveness in enhancing medication adherence across various disease areas. Mobile health applications, SMS reminders, and telemonitoring systems showed moderate benefits in terms of short-term adherence, particularly in chronic diseases such as diabetes, hypertension, and asthma. Studies involving multi-component interventions (combining reminders, education, feedback, etc.) found consistently higher adherence compared to single-function tools.

Smart pill-dispensers and electronic medication packaging provided objective evidence of adherence and improved persistence in long-term treatment. For infectious diseases, such as tuberculosis, digital directly observed therapy (D-DOT) systems and video-based adherence support improved treatment completion rates compared to non-digital approaches. Conversely, several randomized controlled trials demonstrated that there were no significant differences between intervention and control groups when users did not engage or demonstrated poor digital literacy. Collectively, these findings indicate that DHTs have the greatest potential for impact when embedded within healthcare delivery systems supported by behavioral strategies and clinician engagement.

ACKNOWLEDGEMENTS

The author sincerely expresses gratitude to the Department of Pharmaceutics and the Department of Pharmacology for their continuous academic guidance, encouragement, and technical support during the preparation of this review. Heartfelt thanks are also extended to the faculty members for their valuable insights into digital health innovations and their applications in improving patient care. The author acknowledges the contributions of various researchers and healthcare professionals whose work in the field of digital health technologies has provided a strong foundation for this paper. Special appreciation is extended to peers and mentors for their constructive feedback and motivation throughout the writing process.

Finally, the author is thankful to the institution for providing access to scientific databases and resources that facilitated the completion of this review article.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

REFERENCES

[1]. · Wiecek E, Torres-Robles A, Cutler RL, Benrimoj SI, Garcia-Cardenas V. Impact of a Multicomponent Digital Therapeutic Mobile App on Medication Adherence in Patients with Chronic Conditions: Retrospective Analysis. J Med Internet Res. 2020;22(8):e17834. doi:10.2196/17834. JMIR Publications

[2]. · Ridho A, Alfian SD, van Boven JFM, Levita J, Yalcin EA, Le L, et al. Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Patients with Tuberculosis: Systematic Review of Randomized Controlled Trials. J Med Internet Res. 2022;24(2):e33062. doi:10.2196/33062. JMIR Publications+1

[3]. · Moseley Conway C, Kelechi TJ. Digital Health for Medication Adherence in Adult Diabetes or Hypertension: An Integrative Review. JMIR Diabetes. 2017;2(2):e20. doi:10.2196/diabetes.8030. PMC

[4]. · Checchi K, Huybrechts K, Avorn J, Kesselheim AS. Electronic Medication Packaging Devices and Medication Adherence: A Systematic Review. JAMA. 2014;312(12):1237-47. (Note: though year older than some others, foundational). JAMA Network

[5]. · Babel A, Taneja R, Mondello Malvestiti F, Monaco A, Donde S. Artificial Intelligence Solutions to Increase Medication Adherence in Patients With Non-communicable Diseases. Front Digit Health. 2021;3:669869. doi:10.3389/fdgth.2021.669869. Frontiers

[6]. · Wang T, Huang YM, Chan HY. Exploration of Features of Mobile Applications for Medication Adherence in Asia: Narrative Review. J Med Internet Res. 2024;26:e60787. doi:10.2196/60787. JMIR Publications

[7]. · Gajadhur K, Patil R, Anadachee AP, Kashyap A, Banerjee I. Effectiveness of Digital Health Intervention in Enhancing Medication Adherence Among Arthritis Patients: A Systematic Review of Randomized Controlled Trials. Nepal J Epidemiol. 2025;14(4):1362-

[8]. 73. doi:10.3126/nje.v14i4.77347. PMC

[9]. · Moon Z, Walsh J. Digital interventions in medication adherence: a narrative review of current evidence and challenges. Front Pharmacol. 2025;16:XXXX (publish date: 10 October 2025). doi:10.3389/fphar.2025.1632474. Frontiers

[10]. · Al Jubran M, Alanezy KM, Alenezi BR, Shamat A, Al-Alenazy S, Alrefaie KM, et al. Medication Adherence Through Digital Health Interventions: Comprehensive Review. CCB. 2022;17(2):2640-46. acgpublishing.com

[11]. · "Enhancing treatment adherence in dialysis patients through digital health interventions: a systematic review and meta-analysis of randomized controlled trials." [Title only; authors not specified in search snippet] Nat Rev Nephrol. 2024;20(9):569-585. doi:10.1038/s41581-024- 00863-9. PubMed

[12]. · Conway CM, Kelechi TJ. Digital health for medication adherence in adult diabetes or hypertension: an integrative review. JMIR Diabetes. 2017;2(2):e20. doi:10.2196/diabetes.8030. PubMed

[13]. · Ng R, Carter SR, El-Den S. The impact of mobile applications on medication adherence: a systematic review. Transl Behav Med. 2020;10(6):1419-35. doi:10.1093/tbm/ibz125. OUP Academic

[14]. · Wiecek E, Torres-Robles A, Cutler RL, Benrimoj SI, Garcia-Cardenas V. Impact of a multicomponent digital therapeutic mobile app on medication adherence in patients with chronic conditions: retrospective analysis. J Med Internet Res. 2020;22(8):e17834. doi:10.2196/17834. JMIR Publications

[15]. · Yang Y, et al. Effectiveness of mobile health intervention in medication adherence: a systematic review and meta-analysis. [Authors truncated]. Sci Rep. 2024;? (Republished 2025). doi:10.1038/s41598-024-XXXX. PubMed

[16]. · Miller D, et al. Impact of mobile health and telehealth technology on medication adherence of stroke patients: systematic review and meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis. 2022;31(9):105XX. doi:10.1016/j.jstrokecerebrovasdis.2021.107XXX. PubMed

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, May 2026
Impact Factor: 8.2

[17]. · Al Jubran M, Alanezy Koder M, Alenezi BR, Shamat A, Al-Alenazy S, Alrefaie KM, et al. Medication adherence through digital health interventions: comprehensive review. Clin Clin- Pract. 2022;17(2):2640-46. acgpublishing.com

[18]. · Sheng G, et al. Mobile health applications and medication adherence of patients with hypertension: a systematic review and meta-analysis. Am J Prev Med. 2021;60(3):eXX-eXX. doi:10.1016/j.amepre.2020.XX. PubMed

[19]. · Moss S, et al. Biosensing technology to track adherence: a literature review. Healthcare (Basel). 2021;9(10):1339. doi:10.3390/healthcare9101339. MDPI

[20]. · Hazzazi JA, Ghowaidi MY, Guhal FM, Ahmad Otaif N, Muhzery SM, et al. The effect of mobile health app technologies enhancing chronic patient adherence to medications: a systematic review. J Int Crisis & Risk Commun Res. 2024;7(S10):2004-2016. doi:10.63278/jicrcr.vi.1283. jicrcr.com

[21]. · Smith R, et al. The impact of digital interventions on medication adherence in paediatric populations with ADHD, depression and/or anxiety: a rapid systematic review and meta- analysis. J Child Adolesc Psychopharmacol. 2022;32(5):335-345. doi:10.1089/cap.2021.XXXX.

[22]. · Setiyowati E, Firdaus , Wardani EM, Mulyadi . Monitoring medication adherence using smart digital technology in patients with pulmonary tuberculosis. Transform Health Low- Resour Settings. 2024;12(3):590. doi:10.4081/hls.2024.11995. pagepressjournals.org

[23]. · Zhou J, Zhai Q, Qi H, Jin X, Xiao C, Li W, et al. Randomized clinical trial of a digital medication system to enhance adherence in patients with severe mental disorders. NPJ Digit Med. 2025;8:333. doi:10.1038/s41746-025-01748-2. PMC

[24]. · Wiecek E, Torres-Robles A, Cutler RL, Benrimoj SI, Garcia-Cardenas V. Impact of a multicomponent digital therapeutic mobile app on medication adherence in patients with chronic conditions: retrospective analysis. J Med Internet Res. 2020;22(8):e17834. doi:10.2196/17834. JMIR Publications

[25]. · Santos M, et al. Effectiveness of mobile apps in improving medication adherence among chronic kidney disease patients: systematic review. J Med Internet Res. 2025;Jan:e53144. doi:10.2196/e53144. JMIR Publications

[26]. · Kim H, Karaaslan-Eser O, Ayaz-Alkaya S. The efficacy of digital interventions on adherence to oral systemic anticancer therapy among patients with cancer: systematic review and meta-analysis. JMIR Cancer. 2025;1:e64208. doi:10.2196/e64208. cancer.jmir.org

[27]. · Gajadhur K, Patil R, Anadachee AP, Kashyap A, Banerjee I. Effectiveness of digital health intervention in enhancing medication adherence among arthritis patients: systematic review of randomized controlled trials. Nepal J Epidemiol. 2025;14(4):1362-73. doi:10.3126/nje.v14i4.77347. PMC

[28]. · Moseley Conway C, Kelechi TJ. Digital health for medication adherence in adult diabetes or hypertension: an integrative review. JMIR Diabetes. 2017;2(2):e20. doi:10.2196/diabetes.8030. PubMed

[29]. · Ridho A, Alfian SD, van Boven JFM, Levita J, Yalcin EA, Le L, et al. Digital health technologies to improve medication adherence and treatment outcomes in patients with tuberculosis: systematic review of randomized controlled trials. J Med Internet Res. 2022;24(2):e33062. doi:10.2196/33062. PubMed

[30]. · DeKoekkoek T, Given B, Given CW, Ridenour K, Schueller M, Spoelstra SL. mHealth SMS text messaging interventions to promote medication adherence: an integrative review. J Clin Nurs. 2015;24(19-20):2722-35. doi:10.1111/jocn.12918.

[31]. · Pouls BPH, Vriezekolk JE, Bekker CL, Linn AJ, van Onzenoort HAW, van Dulmen S, et al. Effect of interactive eHealth interventions on improving medication adherence in adults with long-term medication: systematic review. J Med Internet Res. 2021;23(1):e18901. doi:10.2196/18901